SCHEMBL2425142

SCHEMBL2425142

CS(=O)(=O)N1CCC(Nc2cc(C(=O)O)ccc2C(N)=O)CC1

nearest known ligand 0.49

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ JAK2 O60674 2/20 0.49
▸ JAK3 P52333 2/20 0.49
▸ ALDH1A1 P00352 1/20 0.45
▸ SYK P43405 3/20 0.44
▸ BTK Q06187 1/20 0.43
▸ CDK2 P24941 6/20 0.42
▸ CCNE1 P24864 4/20 0.42
▸ CCNA2 P20248 1/20 0.42
▸ CCNA1 P78396 1/20 0.42
▸ IDO1 P14902 1/20 0.42
▸ CREBBP Q92793 2/20 0.41
▸ HCAR3 P49019 1/20 0.41
▸ JAK1 P23458 1/20 0.41
▸ F11 P03951 1/20 0.41
▸ CDK1 P06493 1/20 0.40
▸ CDK4 P11802 1/20 0.40
▸ CCND1 P24385 1/20 0.40
▸ MAPT P10636 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13451028 0.93 JAK2 (0.51) JAK2JAK3ALDH1A1SYKBTK
SCHEMBL2426799 0.84 HCAR3 (0.55) ALDH1A1CREBBPHCAR3MAPT
SCHEMBL12294374 0.81 CREBBP (0.43) BTKCREBBPHCAR3
SCHEMBL2426793 0.81 HCAR3 (0.57) SYKCREBBPHCAR3
SCHEMBL2426534 0.81 HCAR3 (0.57) CREBBPHCAR3
SCHEMBL2424448 0.80 HCAR3 (0.56) CREBBPHCAR3
SCHEMBL13885493 0.80 CREBBP (0.40) ALDH1A1BTKCREBBPHCAR3
SCHEMBL2422533 0.79 HSP90AA1 (0.53) HCAR3
SCHEMBL2422536 0.79 HSP90AA1 (0.53) HCAR3
SCHEMBL28790643 0.78 HCAR3 (0.40) BTKCREBBPHCAR3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101910168-B Tropane compounds EXELIXIS INC 2014-07-30 — — CN disclosed
US-8012956-B2 Tropane compounds EXELIXIS, INC. (US) 2011-09-06 — — US disclosed
US-8012956-B2 Tropane compounds EXELIXIS, INC. (US) 2011-09-06 — — US disclosed
CN-101910168-A Tropane compounds EXELIXIS INC 2010-12-08 — — CN disclosed
EP-2074120-B1 TROPANE COMPOUNDS EXELIXIS INC (US) 2010-03-03 — — EP disclosed
EP-2074120-A1 TROPANE COMPOUNDS Exelixis, Inc. (US) 2009-07-01 — — EP disclosed
US-20090163471-A1 Tropane compounds EXELIXIS, INC. 2009-06-25 — — US disclosed
US-20090163471-A1 Tropane compounds EXELIXIS, INC. 2009-06-25 — — US disclosed
WO-2009055077-A1 TROPANE COMPOUNDS EXELIXIS, INC. (US) 2009-04-30 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090163471-A1 Tropane compounds ADRA1B, ADRA2B, ADRB2 JAK2 3332/4885JAK3 4162/4885ALDH1A1 323/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback